首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1535673

碳青霉烯市场 - 按药物类别（美罗培南、亚胺培南、厄他培南、多尼培南）、应用（泌尿道、血液和腹内感染、细菌性脑膜炎）、配销通路- 全球预测（2024 - 2032）

Carbapenem Market - By Drug Class (Meropenem, Imipenem, Ertapenem, Doripenem), Application (Urinary Tract, Bloodstream, & Intra-Abdominal Infections, Bacterial Meningitis), Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年06月12日 | 出版商:

Global Market Insights Inc. | 英文 167 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在不断增长的医疗保健需求的推动下，全球碳青霉烯市场预计从 2024 年到 2032 年将实现 5% 的复合年增长率。世界卫生组织(WHO) 报告称，到2050 年，全球60 岁及以上人口预计将增加近一倍，从2015 年的12% 增至22%。中等收入国家。人口老化更容易患慢性病和感染，增加了对碳青霉烯类等有效抗生素的需求。

此外，医院获得性感染的高盛行率进一步促进了市场成长，因为碳青霉烯类药物经常用于治疗严重的医院获得性感染。

整个碳青霉烯类市场根据药物类别、应用、配销通路和区域进行细分。

亚胺培南细分市场将在 2024 年至 2032 年期间经历大幅成长。製药公司正专注于此类药物来解决严重的细菌感染。亚胺培南的广谱活性和抗抗药性菌株的功效使其对于治疗危及生命的疾病至关重要。增强的生产能力和严格的监管合规性确保了高品质的亚胺培南供应，满足医疗机构对强效抗生素不断增长的需求。

到 2032 年，血流感染应用领域将占据重要的碳青霉烯类市场。碳青霉烯类，包括亚胺培南，由于其广谱抗菌特性，在控制这些感染方面发挥关键作用。血流感染盛行率的增加，特别是在医院环境中，推动了碳青霉烯类药物的采用。诊断技术和医疗基础设施的进步透过实现及时、准确的感染管理进一步支持市场成长。

由于快速城市化、医疗支出增加和传染病高发，亚太地区碳青霉烯类市场将在 2024 年至 2032 年期间实现可观的成长。完善的医疗保健系统、对医学研究的大量投资以及健全的监管框架确保了药品的品质和安全。政府对医疗保健计划的支持以及该地区领先製药公司的存在推动了创新和生产，促进了亚太地区碳青霉烯市场的强劲增长。

产业生态系统分析
产业影响力
- 成长动力
  - 抗生素抗药性感染的盛行率不断增加
  - 临床研究的高研发投资
  - 院内感染发生率不断上升
  - 提高认识和诊断进步
- 产业陷阱与挑战
  - 碳青霉烯类抗生素生产成本高
  - 副作用和安全问题
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
2023 年定价分析
- 按地区
- 按关键人物
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
美罗培南
亚胺培南
厄他培南
多尼培南
其他药物类别

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
泌尿道感染
血流感染
腹腔内感染
细菌性脑膜炎
其他应用

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AstraZeneca PLC
Aurobindo Pharma
Daewoong Pharmaceuticals Co., Ltd.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Kopran Limited
Lupin Limited
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Shenzhen Haibin Pharmaceutical Co. Ltd.
Sun Pharmaceutical Industries Ltd.
The Menarini Group
Venus Remedies Ltd.
Viatris Inc.

简介目录

Product Code: 9836

Global Carbapenem Market is set to achieve a 5% CAGR from 2024 to 2032, driven by increasing healthcare demands. The World Health Organization (WHO) reports that the global population aged 60 and above is projected to nearly double from 12% in 2015 to 22% by 2050. By then, 80% of older individuals will reside in low- and middle-income countries. This aging demographic is more prone to chronic conditions and infections, escalating the need for effective antibiotics such as carbapenems.

In addition, the high prevalence of Hospital-Acquired Infections further contributes to the market growth as Carbapenems are often used to treat severe hospital-acquired infections.

The overall Carbapenem Market is segmented based on drug class, application, distribution channel, and region.

The Imipenem segment will experience substantial growth over 2024-2032. Pharmaceutical companies are focusing on this drug class to address severe bacterial infections. Imipenem's broad-spectrum activity and efficacy against resistant strains make it crucial in treating life-threatening conditions. Enhanced production capabilities and stringent regulatory compliance ensure high-quality imipenem supply, meeting the rising demand for potent antibiotics in healthcare settings.

The Bloodstream infections application segment will capture a significant Carbapenem market share by 2032. Bloodstream infections require immediate and effective treatment to prevent severe complications and mortality. Carbapenems, including imipenem, play a critical role in managing these infections due to their broad-spectrum antibacterial properties. Increased prevalence of bloodstream infections, particularly in hospital settings, drives the adoption of carbapenems. Advances in diagnostic technologies and healthcare infrastructure further support market growth by enabling timely and accurate infection management.

Asia Pacific carbapenem market will drive commendable gains throughout 2024-2032 due to rapid urbanization, increasing healthcare expenditures, and a high prevalence of infectious diseases. Well-established healthcare systems, significant investment in medical research, and robust regulatory frameworks ensure the quality and safety of pharmaceutical products. Government support for healthcare initiatives and the presence of leading pharmaceutical companies in the region drive innovation and production, contributing to the strong growth of the carbapenem market in Asia Pacific.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of antibiotic-resistant infections
  - 3.2.1.2 High R&D investments in clinical research
  - 3.2.1.3 Growing incidence of hospital-acquired infections
  - 3.2.1.4 Increased awareness and diagnostic advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of production of carbapenem-based antibiotics
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Meropenem
5.3 Imipenem
5.4 Ertapenem
5.5 Doripenem
5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Urinary tract infections
6.3 Bloodstream infections
6.4 Intra-abdominal infections
6.5 Bacterial meningitis
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa